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II. ABSTRAK 
 
Latar Belakang: P53 adalah sejenis genetik penahan tumor. Frekuensi mutasi genetik p53 di 
dalam kanser payudara adalah 30% (linkungan 15 hingga 71%). Ianya mempunyai kaitan 
dengan prognosis yang tidak baik. Kaijan ini dijalankan untuk menganalisa mutasi genetik 
p53 dengan klinikalpathologikal kanser payu dara dan kesesuaian serum pesakit untuk 
mengesan autoantibodi p53. 
 
Kaedah: Kajian ini dijalankan di Hospital Seberang Jaya dan Institut Perubatan dan 
Pergigian Termaju, Universiti Sains Malaysia. Seramai enam puluh empat pesakit yang 
mempunyai tisu segar kanser payudara yang disimpan dibawah -80°C dan data 
klinikopathologikal yang lengkap dimasukkan didalam kajian ini. DNA dari tisu segar kanser 
payudara diesktrak dan 10 sampel DNA ini dihantar bagi ujian DNA sekuensi. Sampel 
selebihnya dijalankan analisa ‘Polymerase Chain Reaction’. Serum pesakit-pesakit ini juga 
diambil untuk mengesan autoantibodi p53. 
 
Keputusan: Purata umur pesakit di dalam kajian ini adalah 52.45±9.51 yrs. Majoriti pesakit 
adalah berketurunan Melayu iaitu 67.2% diikuti India 17.2 dan Cina 15.6%. Seramai 51.6% 
pesakit menjalankan CT scan dan 14.1% pesakit kanser sudah di tahap 4 kanser payudara. 
Kadar mutasi genetik p53 bagi rs1042522 adalah 15.7% . Bagi rs59758982, kadar mutasi 
adalah 54.7% bagi “Deletion A” dan 45.3% bagi “Wild Type A”. rs35069695 pula 
menunjukan kadar mutasi “Deletion A” adalah  87.5% dan “Wild Type A” adalah 12.5%. 
rs376546152 pula menunjukan kadar mutasi bagi “Deletion GAA” sebanyak 92.2 %. Secara 
keseluruhan, tiada kaitan antara mutasi genetik p53 dengan perilaku klinikopathologikal 
kanser payudara kecuali bagi mutasi genetik rs59758982 menunjukkan kaitan dengan 
vi 
 
metastasis di mana p value adalah 0.04. Kajian ini juga menunjukkan bahawa hanya 20.3% 
pesakit kanser payudara mempunyai sera auto antibodi p53 dan ianya tidak mempunyai 
kaitan dengan mutasi genetik p53.  
 
Rumusan: Di dalam kajian ini, mutasi genetik p53 didalam tisu segar didapati tiada 
hubungan dengan klinikopathologikal karakter kanser payudara dan penggunaan serum untuk 
mengesan autoantibodi p53 adalah tidak konklusif. 
 
Kata Kunci: kanser payudara, mutasi genetik p53, serum autoantibodi p53 serum, 
rs1042522, rs59758982, rs35069695, rs376546152 
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III. ABSTRACT 
 
Background: P53 is a tumour suppresor gene. In breast cancer, p53 gene mutation were 
noted with frequency of about 30% (range 15 to 71%) and associated with poor prognosis. 
This study was perform determine p53 mutation association with clinicopathological 
characteristic in breast cancer and to assess the suitability of patients’ serum to detect p53 
autoantibody. 
  
Methods: This study conducted in Hospital Seberang Jaya and Institut Perubatan dan 
Pergigian Termaju, Universiti Sains Malaysia. Six four breast cancer patients with available 
fresh breast cancer tissue that been kept under -80°C and with complete clinicopathological 
data involve in this study. These fresh breast tissues DNA extracted and 10sampels sent for 
DNA sequencing. The remaining 54samples proceeded with Polymerase Chains Reaction 
analysis based on the result from DNA sequencing. The serum of these patients was also 
taken for p53 autoantibody study using ELISA method. 
 
Results: The mean age of the patients in this study was 52.45±9.51 years. Most of the 
patients were Malay with 67.2% followed by Indian and Chinese with 17.2% and 15.6% 
respectively. About 51.6% of these patients undergone CT scan staging and 14.1% has distant 
metastases. p53 gene mutation prevalence showed rs1042522 only has 15.7%  mutation. 
There was 54.7% Deletion A and 45.3% Wild Type A detected in rs59758982,  87.5% 
Deletion A and 12.5% Wild Type A in rs35069695 and 92.2 % recorded for Deletion GAA 
in rs376546152. There was no significant result between these mutation with breast cancer 
molecular classification and breast cancer aggressiveness except for rs59758982 shows 
significant result with p value 0.04 (p <0.05). In regards on for p53 serum auto antibodies, 
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20.3% of the patients noted to be positive but it has no significant association with p53 gene 
mutations.. 
  
Conclusion: In this study, tissue p53 genetic mutation has no significant association with 
clinicopathological characteristic of breast cancer and the use of serum p53 auto antibody as 
biomarkers is inconclusive. 
 
Keywords: breast cancer, p53 gene mutation, p53 serum auto antibodies, rs1042522, 
rs59758982, rs35069695, rs376546152 
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1.0  INTRODUCTION 
Breast cancer is a distressful disease affecting patient overall wellbeing. It affects both 
genders and all ethnicity around the world. Each year, this illness affects more than 1 million 
people worldwide especially women.  Worldwide about 1.67million new cases were 
diagnosed in the year 2012.  This represents 12% off all new cases and 25% of all cancer in 
women.1 However; the incidence of breast cancers is much lower in men which account for 
only 1% of all cancer in men.2  
According to GLOBOCAN 2012, breast cancer is on the rise in developing countries 
(883000 new cases) compare to the developed countries (794000).1  
In 2012, it is estimated that worldwide 522000 women succumbed to breast cancer.1 It 
is the most frequent cause of cancer death in women in less developed regions and now the 
second cause of cancer death in more developed area in the world.1 
National Cancer Registry Malaysia (2007) has reported that, breast cancer was the 
most frequently diagnosed cancer in women in all ethnic groups with a total of 3,242 cases, 
accounting for 18.1% of all cancers cases and 32.1% of female cancers.3,4, Chinese had the 
highest incidence with an ASR of 46.8 per 100000 population followed by Indian women 
with an ASR 38.1 per 100000 population and  Malay women with an ASR 30.4 per 100000 
population. The incidence is steadily increasing with age and peak in the 50-59 age groups.3,4 
 According to Penang Cancer Registry report in 2004 until 2008, there were 1699 
cases of breast cancer reported from both government and private hospital.5 Breast cancer was 
also the commonest cancer notified among women in Hospital Seberang Jaya with 114 cases 
in 2012 and 103 cases in 2013.6,7 
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1.1 LITERATURE REVIEW 
1.1.1  BREAST CANCER  
The pathophysiology of breast cancer has not been fully understood. It is believed to 
occur as a result of multiple factors involving oncogenes, tumour suppressor gene defect, 
hereditary gene, reproductive factors, radiation exposure and life-style. Genes whose 
alterations cause gain-of-function effects are referred to as oncogenes. Meanwhile, genes that 
cause loss-of-function effects and contribute to the malignant phenotype are known as tumour 
suppresor genes.8 So far the known predisposing factors for breast cancer are BRCA1 and 
BRCA2 genetic mutation, women with first degree relatives with breast cancer at young age, 
reproductive factors i.e women with prolonged oestrogen exposure (early menstruation, oral 
contraceptive pills, nulliparous), body mass index more 25 and alcohol consumption more 
than 10g/day.4 
 Commonly, breast cancer arises either from ductal or lobular cells of the breast tissue. 
However, there are uncommon type of breast cancer including sarcomas, mucinous, 
myoepitheliomas and lymphomas.9   
 Currently, breast cancer prognosis is determine by its tumour histological grading, 
stage based on TNM staging and oestrogen, progesterone HER-2 status.4 In contrarily, there 
are many other study has been done on breast cancer including the studies on ki-67, VEGF, 
p21, CEA, ca 125 and p53 gene to improve breast cancer prognosis and aid in breast cancer 
management. However, despite all the research that has been done, there is no conclusive 
result in this matter.8.9  
 
1.1.2 P53 AS TUMOR SUPPRESOR GENE 
 The most studied tumour suppressor gene in all cancers is the p53 gene. Initially; p53 
was classified as an oncogene because of it closed relationship with the oncogenic DNA virus 
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SV40 large T protein. However, isolation of tumour cell complementary DNA demonstrated 
that p53 in tumour contains a point mutation and has tumour suppressor function.10 P53 is the 
first tumour suppressor gene and was identified in year 1979.  
 P53 gene plays important role to inhibit and eliminate the proliferation of abnormal 
cells. In normal condition, it is in standby mode. It gets activated once there are cellular 
stresses such as are genotoxic (DNA alterations induced by irradiation, carcinogens, cytotoxic 
drugs), hypoxia, oncogenes activation and loss of normal cell contact.11,12  
 P53 also has many mechanisms of anticancer function, and plays a role in apoptosis, 
genomic stability, and inhibition of angiogenesis. It function via several mechanism; i.e. DNA 
repair protein when DNA sustained damage, holding cell at GI/S regulating point so repair is 
possible, and initiate apoptosis if repair impossible.13 This action occurred in response to 
cellular stress with main aim to prevent accumulation of genetic changes and damaged cell.14 
 P53 gene is located on the short arm of chromosome 17 (17p13.1).13 As a ‘guardian of 
the genome’, inactivation of p53 gene is a result of p53 deletion, p53 mutation or aberrant p53 
function.10 It can either be a rare germ line mutation (as in case of Li-Fraumeni’s Syndrome; 
autosomal familial disorder) or more commonly a somatic mutation.12 It’s mutation are 
characterised by a high prevalence of missense mutations found primarily in exons 5-8 in 
DNA binding domain.13 The spectrum of mutation in breast cancer is similar to other cancer 
with less G:C to T:A transversions, and more A:T to G:C transitions.14 P53 gene act on a 
damaged cell via its p53 protein. Hence any mutation of the gene will produce mutated p53 
protein. 
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1.1.3 DETECTION OF P53 MUTATION 
 P53 genetic mutation in breast cancer can be analysed via few methods, but the 
sensitivity and specificity varies greatly. P53 mutation can be detected by using fresh tumour 
tissue, fresh paraffin embedded tumour tissue or blood.15 Molecularly, the detection of p53 
mutation can either be by using the DNA or the antibodies. Methods of detection can either be 
via immunohistoschemically (IHC), single strand conformational polymorphism (SSCP), 
Polymerase Chain Reaction (PCR) and DNA direct sequencing, genomic microarray, ligase 
chain reaction or yeast reporter functional assay.15 
  According to Gilbert et. al and Andre. M.O. et. al, most study in regards of p53 
mutation use IHC (paraffin embedded tumour tissue) in view of it being a rapid and 
inexpensive test comparing to other method.13,15 However, it is subjected to low accuracy, 
high false positive and high false negative result. The most accurate test with high specificity 
is by using yeast reporter functional assay in fresh tumour tissue or blood. However, this test 
is expensive and mainly use for germline detection of Li Fraumeni syndrome in research. This 
test needs to be combined with PCR to detect genetic mutation.10, 15 
 The test that is easily available and cost effective is PCR and direct sequencing. These 
tests are more accurate than SSCP and IHC. Its false negative result is only about 2 to 4%. 
However, it is limited to detect p53 genetic mutation and not to detect mutation of stabilised 
protein or posttranslational modifications.10, 15 
 
1.1.4 P53 AUTOANTIBODIES IN SERUM  
 After the discovery of p53 as tumour suppressor gene, Crawford et. al proceeded with 
further study in this matter by assessing the presence of autoantibody against p53 in serum of 
patients with breast cancer. Out of 155 patients with breast cancer, 14(9%) patients were 
reported to have p53 autoantibody circulating in their serum.16 From this pioneer study, 
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multiple subsequent study were done to analysed the presence of p53 autoantibody in serum 
and its suitability as tumour biomarkers and prognostic indicator in breast cancer. 
 The presence of P53 autoantibody in breast cancer patient is still in debates. It was 
postulated that accumulation of p53 in the tumour is the major factor that triggers the 
development of the humoral immune response.17 However; several studies showed that this is 
not the case. Some patient with detectable p53 autoantibody in the serum have undetected 
level of p53 in the tumour using IHC method.18, 19 It was also postulated that p53 
autoantibody is the result of p53 genetic mutations.17  
 In a study by G.A Balogh et.al, out of 55 patients, 16.36% were found positive for p53 
autoantibody and 52.73% positive for p53gene by IHC method. However, all positive p53 
autoantibody has positive p53 IHC evaluation.9 
 On the other hand a study by K. Angelopopou et.al. on 16 patients using PCR and 
serum antibody found only 5 patients have detectable mutation in p53 gene as well as 
antibodies. The abnormalities detected were missense point mutations and nonsense 
mutations.17 
 Another study by T.I Hewala et.al showed that the presence of serum p53 
autoantibody remain the same pre and post surgery as well as post chemotherapy using FAC 
regimes (5-Fluorouracil, Adriamycin and Cyclophosphamide). This can either be good as this 
can be used to detect the p53 autoantibody despite procedures done but bad as a monitoring 
method of the treatment response.20 
 
1.1.5 EPIDEMIOLOGY OF P53 MUTATION IN BREAST CANCER 
 P53 is deleted or mutated in up to 50% of all cancer.21  In breast cancer, p53 gene 
mutation were noted with frequency of about 30% (range 15 to 71%).22,23  
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 A study done in Malaysia by Mdzin R et. al., using immunohistochemistry method, 
p53 over expression was detected in 45.8% of the cases (27 patients out of 59 patients).24  
 In another study done by FS Al-Joudi et. al., 29.6% p53 overexpression detected in 
382 breast cancer patients using immunohistochemistrical method.25  
 According to Daphne SC Lee et. al., in young breast cancer patients (less than 35years 
old), 6% (5/83) of Asian BRCA negative patients has exonic germ line mutation of p53.26 In 
association with other germ line mutation, p53 mutation is also found commonly in BRCA1 
and BRCA2 patients.15 
 Histologically, frequency of p53 genetic mutation was found highest in medullary 
breast cancer and lowest seen in papillary or mucinous type.15 p53 mutations are also more 
common in ductal carcinoma than in lobular carcinoma.10,27 p53 abnormalities also associated 
with higher grade cancers, aneuploid tumours and high mitotic rate tumours.12,28 
 Beside that, p53 mutation in breast cancer is widely reported to be associated with low 
level of oestrogen and progesterone receptors.27,28,29,30 Oestrogen receptors(ER) and 
progesterone receptors(PR) are known markers for less aggressive tumours with good 
response for hormonal therapies.28 
 Furthermore, Pavel Rossner J. et.al. also found that women with ER/PR negative 
tumours had almost 4 fold higher risk of having p53 mutation comparing to ER/PR positive 
patient.31 
 
1.1.6 P53 IN BREAST CANCER PROGNOSIS AND SURVIVAL  
 P53 gene mutation is associated with high grade tumour (histology grade III and 
more), worse tumour staging (stage III and IV), triple negative breast cancer and reduced 
survival rates. 4,12,23,28 Triple negative breast cancers are defined as lack of oestrogen receptors 
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(ER), progesterone receptors (PR) and c-erB-2/Her2 expression.32 These triple negative 
patients are not responsive to hormonal therapy and monoclonal antibodies treatment. 
 The known importance of detecting mutant P53 gene in breast cancer tissue is its roles 
as prognostic indicator. Multiple studies have shown that p53 mutation were associated with 
worse prognosis and shorter survival rates. However, few studies also indicate that the 
presence of p53 as independent prognostic indicator is weak.12 Thus; combining with other 
indicators such as ER/PR, cerB-2/HER-2 and Ki-67 is more effective as prognostic indicator. 
 It was found by Hiroko Yamashita et.al that coexistence of HER2 over expression and 
p53 protein accumulation is a strong prognostic molecular marker in breast cancer.33 
 In study done by Tadahiro N et.al, sera positive p53 autoantibody patients is 
significantly correlated with breast cancer histological grade 3and above (p value= 0.002). 
They also found that the proportion of triple negative tumours significantly higher among this 
patient (p=0.003).34  
 Kulie a et. al. also gave the same result as their study found that sera positive p53 
autoantibody in breast cancer patients has higher tumour size, higher tumour grade, positive 
axillary lymph nodes, and ER/PR negativity.35 
Another concern in prognosis and survival of breast cancer patients is metastases. 
According to P. Yang et. al., high p53 expression was associated with advanced TNM stage 
(p=0.011), multiple organ involvement (p=0.066) and shorter disease free survival 
(p=0.004).36 
 A molecular study by Antti A et.al., found that mutant p53 breast cancer tumour 
initiated myosin-X (Myo-10) dependent cell invasion cascade. Myo-10 is highly expressed in 
breast cancer and mediates adhesion, migration, invasion and metastases of cancers cell in 
vitro and in vivo.37 
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 Regarding survival in patients with p53 mutations, a study on 700 breast cancer 
patients showed disease free survival rates at 5years was only 58% for high positive 
immunochemistry p53 tumours as compare to 80% in negative p53 tumour group.28 
Pavel Rossner J et.al., found that any p53 mutations and missense mutations were 
associated with breast cancer specific mortality (Hazard Ratio HR = 1.7, 95% CI = 1.0-2.8) 
and all cause of mortality (HR=1.5, 95% CI = 1.0-2.4).14 
  
1.1.7 P53 IN CHEMOTHERAPY 
 The poor prognosis of p53 mutation breast cancer patients may be related to the fact 
that this mutation rendered them resistance to certain chemotherapy drug. Anticancer drugs 
act by few ways either by inducing cancer cells apoptosis or causing cell instabilities. 
Example of anticancer drug that is involved in cell apoptosis is the anthracyclines–based drug. 
In an apoptotic genetic program mutations tumour, it could produce insensitivity towards this 
group of anticancer drug.4,39 
 A study conducted by Daniela Kandioler-Eckersberger et.al on value of p53 to predict 
cytotoxic effect of two commonly used chemotherapy regimes in breast cancer showed that, 
in patient with 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) group, treatment failure 
was related to p53 mutation group. The study also showed that there is significant association 
between abnormal p53 and respond to Paclitaxel. This is believe due to, FEC regimes 
considered to induced p53-dependent apoptosis comparing to Paclitaxel that is independent of 
p53 function.40  
 Several studies showed that tumour carrying p53 gene mutations might be less 
sensitive to anthracyclines–based drugs (i.e. epirubicin) comparing to Taxanes-based (i.e. 
Paclitaxel).41,42 A study by Clahsen et. al. also showed that p53 accumulation in response to 
anthracycline-containing regime was associated with poor response.4 
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1.2  RATIONAL OF THE STUDY 
1.2.1 RESEARCH JUSTIFICATION AND BENEFITS 
 P53 genetic mutation in breast cancer in Malaysia is not widely studied. This study 
provided a local data of p53 genetic mutation and its association with clinicopathological 
characteristic in breast cancer. Furthermore, most studies that have been conducted with 
regards to p53 mutation in breast cancer in Malaysia were using formalin fixed breast cancer 
tissue and enzyme immunohistochemistry assay to detect p53 mutation.13,24,25  
 In this study fresh breast cancer tissue that has been preserved in -80°C and allele 
specific PCR technique was use to detect p53 mutation. P53 allele specific PCR technique is 
proven more accurate in detecting p53 genetic mutation.13,15 Concurrently, the same patients’ 
serum was used to detect p53 autoantibody. This was to determine the suitability of p53 
autoantibody in serum as biomarkers in breast cancer patient and aid future management in 
breast cancer patient. 
The main focus of current study was to evaluate p53 genetic mutation amongst fresh 
breast cancer tissue of patient undergone operation and p53 autoantibody in serum. So far, 
data on p53 genetic mutation in breast cancer especially locally is not widely available. The 
possibility to use p53 autoantibody in serum as tumour biomarkers is also yet to be discovered 
and discussed.  
 
1.2.2 RESEARCH QUESTION 
1. Is there any significant association between the clinicopathological characteristic with p53 
mutation in breast cancer? 
2. Can serum p53 autoantibody be used as biomarkers in breast cancer? 
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1.2.3 RESEARCH LIMITATIONS 
These study limitations include small sample size in comparison with incidence of breast 
cancer in the country. Furthermore, the duration of available to conduct this study was also 
limited as even though nineteen mutation and deletion was found in this study, only one 
mutation and three deletion can be perform for all samples. 
 
1.2.4 OBJECTIVES  
GENERAL OBJECTIVES 
1. To determine p53 mutation association with clinicopathological characteristic in 
breast cancer 
2. To assess accuracy of patients’ serum in detecting p53 autoantibody 
 
SPECIFIC OBJECTIVES 
a) To determine the profiling data (age, ethnicity, duration of symptoms, risk factor, 
clinicopathology staging) of women with breast cancer 
b) To determine prevalence of p53 mutation in Malaysian’s fresh breast cancer 
tissue using PCR technique 
c) To ascertain fresh breast cancer tissue p53 mutation association with ER, PR, 
HER-2 status in patient with breast cancer 
d) To analyse p53 mutation in relations of breast cancer aggressiveness i.e; staging 
(according to Malaysian Clinical Practise Guidelines)  and grading 
e) To evaluate for serum p53 autoantibody suitability as biomarkers in breast cancer. 
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1.2.5 HYPOTHESIS 
ALTERNATIVE HYPOTHESIS (HA) 
a. There is significant association between clinicopathological characteristic and p53 
mutation in breast cancer 
b. Serum p53 autoantibody can be use as biomarkers in breast cancer 
 
NULL HYPOTHESIS (HO) 
a. There is no significant association between clinicopathological characteristic and p53 
mutation in breast cancer 
b. Serum p53 autoantibody cannot be use as biomarkers in breast cancer 
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1. INTRODUCTION 
 
1.1. OVERVIEW 
Breast cancer is a devastating illness as it affects patient’s self-confidence and 
one of the commonest causes of death due to cancer in woman. Breast cancer is one 
of the commonest non squamous cell carcinoma diagnosed worldwide accounts about 
1.38million in 2008.1 National Cancer Registry Malaysia (2007) reported that in 
Malaysia, the female breast cancer is the most frequently diagnosed cancer in women 
in all ethnic groups with total number of 3,242 cases accounted for 18.1% in all 
cancers cases reported and 32.1% female cancers cases.2 
From Penang Cancer Registry report 2004 till 2008, the reported breast cancer 
within that period was 1699patients from both government and private hospital.3 
Breast cancer is also the commonest cancer notified among women in Hospital 
Seberang Jaya with 114 cases in 2012 and 103 cases in 2013.4,5 
Breast cancer believed to occur in result of multiple factors involving 
oncogenes, tumour suppressor gene defect, genetic, environment and life-style. The 
most studied tumour suppressor gene in all cancers is the p53 gene. P53 gene plays 
important role to inhibit and eliminate the proliferation of abnormal cells. In normal 
condition, it is in standby mode. It gets activated once there are cellular 
stresses.6Examples of the stresses are genotoxic (DNA alterations induced by 
irradiation, carcinogens, cytotoxic drugs), hypoxia, oncogenes activation and loss of 
normal cell contact.7In breast cancer, p53 gene mutation changes noted with 
frequency of about 30% (range 15 to 71%).8,9 P53 mutation is associated with high 
grade tumour (histology grade III and more), worse tumour staging (stage III and IV) 
and reduced survival rates. 9,10,11 
Anticancer drugs act on cancer cell either by inducing apoptosis or cause cell 
instability. According to Malaysian Clinical Practice Guideline on Management of 
Breast Cancer November 2010, all early breast cancer patients should receive 
chemotherapy.12Anticancer drug that involve in apoptosis example is anthracyclines–
based drug. However, a genetic program mutations in apoptotic pathway could 
produce resistance tumour.13,14Few present studies done indicate that tumour carrying 
p53 gene mutations might be less sensitive to anthracyclines–based drugs (i.e. 
epirubicin) comparing to Taxanes-based (i.e. Paclitaxel).15,16 
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1.2. LITERATURE REVIEW 
Breast cancer affect both gender, all ethnicity around the world. Commonly, 
breast cancer arises either from ductal or lobular cells of the breast tissue. However, 
uncommon type of breast cancer included sarcomas, myoepitheliomas and 
lymphomas.17 Breast cancer prognosis is currently determine by its tumour 
histological grading, stage based on TNM classification, estrogen, progesterone and 
HER-2 status.2 Beside this, there were many tumour markers and genetic study has 
been performing in breast cancer. These include the studies onki67, VEGF, p21,CEA, 
ca 125 and p53 gene.10,13,15 
P53 is the first tumour suppressor gene identified in year 1979. P53 has many 
mechanisms of anticancer function, and plays a role in apoptosis, genomic stability, 
and inhibition of angiogenesis. It function via several mechanism; i.e. DNA repair 
protein when DNA sustained damage, holding cell at GI/S regulating point so repair 
is possible, and initiate apoptosis if repair impossible.18 This action occurred in 
response to cellular stress with main aim to prevent accumulation of genetic changes 
and damaged cell.11 
p53 gene located on the short arm of chromosome 17 (17p13.1).18 It’s mutation 
are characterised by a high prevalence of missense mutations found primarily in 
exons 5-8 in DNA binding domain.11 The spectrum of mutation in breast cancer 
similar with other cancer with less G:C to T:A transversions, and more A:T to G:C 
transitions.11P53 gene act on a damaged cell via its p53 protein. Hence any mutation 
of the gene will produce mutant p53 protein. 
G.A Balogh et.al study showed that serum mutant p53 protein was elevated in 
invasive breast carcinomas with strong correlation with accumulation of mutant p53 
detected by immunohistochemical.19 
The known important of detecting mutant P53 in breast cancer tissue is its 
release prognostic indicator. Multiple studies have shown that p53 mutation 
associated with worse prognosis and shorter survival rates. According to P. Yang 
et.al.,high p53 expression was associated with advanced TNM stage (p=0.011), 
multiple organ involvement (p=0.066) and shorter disease free survival (p=0.004).20 
PavelRossner J. et.al.found that women with ER/PR negative tumours had almost 4 
fold higher risk of having p53 mutation comparing to ER/PR positive patient.11 
Hiroko Yamashita et.al found that coexistence of HER2 overexpression and 
p53 protein accumulation is strong prognostic molecular marker in breast cancer.21 
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This poor prognosis may be related to the fact that P53 gene mutation 
resistance to certain chemotherapy drug. A study conducted by Daniela Kandioler-
Eckersberger et.al on value of p53 to predict cytotoxic effect of two commonly used 
chemotherapy regimes in breast cancer showed that, in patient with FEC group, 
treatment failure was related to p53 mutation group. The study also showed that there 
is significant association between abnormal p53 and respond to paclitaxel. This is 
believe due to, FEC regimes considered to induced p53-dependent apoptosis 
comparing to paclitaxel that is independent of p53 function.22Another study also 
showed that p53 accumulation in response to anthracycline-containing regime 
associated with poor response.23 
 
1.3. RESEARCH JUSTIFICATION AND BENEFITS 
P53 mutation in breast cancer in Malaysia is not widely study. Hence, this 
study will provide local data of p53 mutation association with clinicopathological 
characteristic in breast cancer. Besides that, most study has been conducted in regards 
of p53 mutation in breast cancer is using formalin fixed and immunohistochemical 
technique in detecting p53mutation in breast cancer tissue. However, in this study 
fresh breast cancer tissue that has been preserved in control environment is use to 
detectp53 mutation using p53 alelle specific PCR technique. Concurrently, the same 
patients’ serum tissue to detect p53 autoantibody. Hence, this will determine the 
suitability of p53mutation in blood or present of p53 autoantibodies in serum as 
biomarkers in breast cancer patient.  
 
1.4. OBJECTIVES 
1.4.1. GENERAL OBJECTIVES 
To determine p53 mutation association with clinicopathological characteristic in 
breast cancer 
 
1.4.2. SPECIFIC OBJECTIVES 
a. To determine the profiling data (age, ethnicity, duration of symptoms, risk 
factor,clinicopathological) of women with breast cancer 
b. To determine prevalence of p53 mutation in Malaysian’s fresh breast cancer 
tissue using PCR technique 
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c. To ascertain fresh breast cancer tissue p53 mutation association with ER, PR, 
HER-2 status in patient with breast cancer 
d. To analyse p53 mutation in relations of breast cancer aggressiveness i.e; staging 
(according to Malaysian Clinical Practise Guidelines)  and grading 
e. To look for serum p53 autoantibody suitability as biomarkers in breast 
cancer. 
 
1.5. RESEARCH QUESTION 
1. Is there any significant association between the clinicopathological characteristic 
with p53 mutation in breast cancer? 
2. Can serum p53 autoantibody be used as biomarkers in breast cancer? 
 
1.6. HYPOTHESIS 
1.6.1. ALTERNATIVE HYPOTHESIS (HA) 
a. There is significant association between clinicopathological characteristic and 
p53 mutation in breast cancer 
b. Serum p53 autoantibody can be use as biomarkers in breast cancer 
 
1.6.2. NULL HYPOTHESIS (HO) 
a. There is no significant association between clinicopathological characteristic 
and p53 mutation in breast cancer 
b. Serum p53 autoantibody cannot be use as biomarkers in breast cancer 
 
2. METHODOLOGY 
 
2.1. RESEARCH DESIGN 
This is a Cross-Sectional study 
 
2.2. STUDY VENUE 
This study will be conducted in Hospital Seberang Jaya and Institut Perubatan dan 
Pergigian Termaju (IPPT), USM 
 
2.3. STUDY DURATION 
This study will be conducted from 1st January 2015 to 30th June 2016 
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2.4. STUDY POPULATION 
Female patients diagnosed with breast cancer in year 2012 until 2015 from Hospital 
Seberang Jaya that undergone mastectomy with axillary sampling or clearance or 
wide-local excision with axillary sampling or clearance. 
 
2.5. SAMPLE SIZE 
Sample Size Calculation: 
Sample size was calculated using sample size calculator for prevalence studies, Naing 
et. al, 2006) 
Estimated prevalence of p53 mutation= 23.6 % (Anita Langerodet. Al; TP53 
mutation status and gene expression profiles are powerful prognostic markers of 
breast cancer, May 2007)24 
Study precision = 11% 
n= 58 
 
 Anticipating a 10% attrition rate, therefore, the expected no of sample is 64. 
 
2.6. SELECTION CRITERIA 
 
2.6.1. INCLUSION CRITERIA 
a. Patient with histologically confirmed of breast cancer. 
b. Breast cancer’s patient that undergone Mastectomy with Axillary Sampling 
or Axillary Clearance or Wide-Local Excision with Axillary Sampling or 
Axillary Clearance 
c. Cases with completed histopathological report including grading, staging, 
ER, PR and HER-2 status 
d. Patient with clinical staging done. (Stage I and II did ultrasonography of the 
abdomen and chest x-ray, Stage III and IV did CT scan of thorax, abdomen, 
pelvic as Malaysian Clinical Guidelines of Breast Cancer) 
e. Patient consented for the p53 mutation study and serum mutant p53 auto 
antibodies study 
f. Patient more than 18 yea 
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2.6.2. EXCLUSION CRITERIA 
a. Patient do not consented for p53 mutation study and serum p53 autoantibody 
study 
b. Patient who has passed away prior to the time this study conducted 
c. Incomplete documentation of patient’s case note 
 
2.7. CONSENT FOR STUDY 
Each patient will be explained regarding the objective and method of the study by 
primary investigator. Informed consent is taken in accordance to Declaration of 
Helsinki, with protocol and statement of informed consent approved by Ethnics 
Committee. Confidentiality of the patient is keep by giving Code Number to patient. 
Only the primary investigator has the list of patient identification card number or 
hospital registration number for reference. 
Patient has no access onto his / her own personal information and study data. 
However, if patient wish to know their result, they are free to call primary 
investigator to get that information. 
 
2.8. RESEARCH TOOLS AND DATA COLLECTION 
Data collection sheet (proforma) is design to obtain the information from patient’s 
case record. Patient is labelled using Code Number to protect patient privacy. Patient 
personal data will only be known by primary investigator where it will keep in a list 
stating patient identification number or registration number. The details on 
demographic including age at diagnosis and ethnicity will be abstracted. The data on 
mode and symptoms at presentation, family history, clinical characteristic, 
histopathological findings, and chest x-ray and ultrasound abdomen or CT scan 
thorax abdomen pelvic will be obtained from patient’s medical record. Patient serum 
is collected on diagnosis. 
 
Serum mutant p53 protein from 10 normal female individual (without any breast 
disease and family history of breast cancer) taken as negative control to test the p53 
ELISAPLUS (auto antibody) kit (Oncogene Research Product, Cambridge MA, USA). 
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2.9. TISSUE  P53 AND SERUM P53 TESTING 
Tissue: 
Patients’ breast cancer tissue will be collected after surgery without being fixed by 
formalin. It will be collected the same day of operation by IPPT staff. The primary 
breast cancer tissue was will be snap frozen and stored at -80ᵒC.  Frozen section will 
be stained with hematoxylin/eosin and were will be reviewed to confirm tumour 
content by the pathologist.  
Allele-specific PCR: 
DNA will be extracted from patients’ tissue and blood samples using Blood/Tissue 
Midi Kit (Qiagen). The presence of mutation in p53 genes will be detected by allele-
specific PCR.  
Serological analysis:  
3ml blood from patient taken at diagnosis in plain bottle. It the centrifuge to obtain 
the serum and separate it from the blood. 
The present of p53 autoantibodies from serum of all patients will be detected using 
the p53 ELISAPLUS (auto antibody) kit (Oncogene Research Product, Cambridge MA, 
USA). The kit will be used to measure circulating antibodies to p53 in human serum 
samples.  
Serums from 10 normal healthy women with no history of breast and any cancers will 
be taken as negative control. 
 
2.10. STATISTICAL ANALYSIS 
The data will be analysed using Statistical Package for the Social Sciences 
(SPSS) software version 20.  Independent T, Pearson’s Chi Square and 
Fisher’s Exact Test will be used to determine the association. P value of less 
than 0.05 is considered statistically significant 
 
2.11. ETHICAL APPROVAL 
Ethical approval applied before conducting the study as patient’s tissue and 
body fluid is needed in this study from UniversitiSains Malaysia Ethical 
Committee and KementerianKesihatan Malaysia. 
 
 
 
20 
 
2.12. STUDY GRANTT 
This study is approved under short term grant Institut Perubatan dan Pergigian 
Termaju by Division of Research and Innovation, University Sains Malaysia. 
 
3. FLOW CHART 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study population:  
Recruitment of patients diagnosed with Breast Cancer at Breast Cancer Clinic, SOPD Hospital 
Seberang Jaya (HSJ) from 2012 until 2015 (LIST OF NAME  WITH AVAILABLE FRESH BREAST 
CANCER TISSUE OBTAINED FROM HISTOPATHOLOGICAL LAB IPPT) 
(N=64) 
 
Performa fill in by Breast Cancer SOPD Staff Nurse and attending doctor  
Consent for study obtained by primary investigator 
Blood for antibodies studies taken and sent to regenerative lab IPPT for serum extraction either 
once confirm breast cancer or patient on patient subsequent follow up (DURING TIME 
PROCEEDING FOR SERUM P53 AUTOANTIBODIES STUDY) 
 
Patient undergone operation: Mastectomy or Wide Local excision 
 
Tissue will be analysed for Histopatological 
examination (grading, ER, PR, Her2 status) by 
pathologist 
Specimen will be sent to regenerative lab, IPPT 
for p53 mutation study screening 
Tissue / Specimen sent to IPPT as fresh specimen 
(without formalin) 
 
All data collected and analyse 
 
Report writing 
Submission  
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4. BUDGET 
Grantt Approval from RCMO, USM with grantt No, CIPPT/6313162  
5. GANTT CHART 
 
6. PLANNED MILESTONE 
 
a. JUNE 2015   :COMPLETION OF DATA COLLECTION  
    COMPLETION OF DATA ANALYSIS 
b. DECEMBER  2015  : PRESENTATION AND REPORT SUBMISSION 
c. MARCH 2015 : WRITING 
d. JUNE 2015   : SUBMISSION 
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PENGENALAN 
Anda dipelawa untuk menyertai satu kajian  penyelidikan secara sukarela untuk kajian mutasi genetic 
p53 didalam pesakit kanser payudara. Genetic p53 merupakan satu gene yang penting dalam pengawal 
sel-sel tumbuh. Apabila genetik ini mengalami mutasi, sel-sel tubuh tidak lagi terkawal maka terjadilah 
tumor. Tumor yang agresif akan menjadi kanser. Kliniko-pathologikal bermaksud, keadaan pesakit 
semasa pemeriksaan dari segi saiz ketumbuha, perebakan kanser ke bahagian lain dan kajian keatas tisu 
specimen pesakit. Serum p53 autoantibodi pula adalah di mana apabila p53 mutasi berlaku ianya akan 
menghasilkan protein yang bermutasi. Untuk memusnahkan protein ini tubuh manusia akan 
menghasilkan antibody secara semula jadi kepada protein yang bermutasi tersebut. Kajian ini 
melibatkan pengambilan darah dari pesakit dan pengambilan tisu kanser payudara dari specimen 
pembedahan.Satu salinan borang maklumat ini akan diberikan kepada anda sekiranya anda bersetuju 
menyertai kajian ini. 
 
TUJUAN KAJIAN  
Kajian ini adalah untuk melihat samaada mutasi genetic p53 berkaitan dengan perilaku klinikal-patologi kanser 
payudara. 
 
KELAYAKAN PENYERTAAN 
Doktor yang bertanggung jawab dalam kajian ini atau salah seorang kakitangan kajian telah 
membincangkan kelayakan untuk menyertai kajian ini dengan anda. Adalah penting anda berterus 
terang dengan doktor dan kakitangan tersebut tentang sejarah kesihatan anda. Andatidakseharusnya 
menyertai kajian ini sekiranyaandatidakmemenuhisemuasyaratkelayakan. 
 
1. Ada telah dikenalpasti menghidap penyakit kanser payudara 
2. Anda telah menjalani pembedahan kanser payudara 
3. Laporan patologi anda lengkap termasuk ‘grading, ‘staging’,ER,PR dan HER-2’ status 
4. Berumur 18 tahun ke atas 
 
PROSEDUR-PROSEDUR KAJIAN 
Pada lawatansusulan anda, setelah anda dikenal pasti menghidapi kanser payudara dari sampel tisu biopsi pada 
lawatan pertama anda akan diterangkan mengenai kajian ini. Sekiranya anda setuju menyertai kajian, darah anda 
sebanyak 3ml akan diambil dan dihantar ke makmal. Anda akan seterusnya menjalani pembedahan atau rawatan 
sebelum pembedahan seperti yang dicadangkan oleh pakar bedah bertugas. Tisu kanser dari pembedahan yang 
telah dilakukan diambil untuk kajian. Kajian yang dilakukan adalah mengenalpasti mutasi genetik p53 dalam tisu 
kanser payudara anda dan di dalam darah anda. Selain itu,  serum dari darah akan dijalankan ujian autoantibodi 
p53. 
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